Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 638526, 8 pages
http://dx.doi.org/10.1155/2015/638526
Review Article

Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer

Hormones and Cancer Division, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St Leonards, NSW 2065, Australia

Received 20 July 2014; Accepted 29 September 2014

Academic Editor: Eileen M. McGowan

Copyright © 2015 Kamila A. Marzec et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Baxter, “IGF binding proteins in cancer: mechanistic and clinical insights,” Nature Reviews Cancer, vol. 14, no. 5, pp. 329–341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. B. E. Forbes, P. McCarthy, and R. S. Norton, “Insulin-like growth factor binding proteins: a structural perspective,” Frontiers in Endocrinology, vol. 3, article 38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Firth and R. C. Baxter, “Cellular actions of the insulin-like growth factor binding proteins,” Endocrine Reviews, vol. 23, no. 6, pp. 824–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. R. C. Baxter, “Circulating levels and molecular distribution of the acid-labile (α) subunit of the high molecular weight insulin-like growth factor-binding protein complex,” Journal of Clinical Endocrinology and Metabolism, vol. 70, no. 5, pp. 1347–1353, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Beattie, K. Phillips, J. H. Shand, M. Szymanowska, D. J. Flint, and G. J. Allan, “Molecular interactions in the insulin-like growth factor (IGF) axis: a surface plasmon resonance (SPR) based biosensor study,” Molecular and Cellular Biochemistry, vol. 307, no. 1-2, pp. 221–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. B. Boldt and C. A. Conover, “Overexpression of pregnancy-associated plasma protein-a in ovarian cancer cells promotes tumor growth in vivo,” Endocrinology, vol. 152, no. 4, pp. 1470–1478, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Nakamura, S. Miyamoto, H. Maeda et al., “Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability,” Biochemical and Biophysical Research Communications, vol. 333, no. 3, pp. 1011–1016, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Yan, L. D. Payet, R. C. Baxter, and S. M. Firth, “Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes,” Endocrinology, vol. 150, no. 11, pp. 4968–4976, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Guix, A. C. Faber, S. E. Wang et al., “Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins,” The Journal of Clinical Investigation, vol. 118, no. 7, pp. 2609–2619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. L. Martin, J. A. Coverley, S. T. Pattison, and R. C. Baxter, “Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol,” Endocrinology, vol. 136, no. 3, pp. 1219–1226, 1995. View at Google Scholar · View at Scopus
  11. S. E. Pratt and M. N. Pollak, “Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media,” Cancer Research, vol. 53, no. 21, pp. 5193–5198, 1993. View at Google Scholar · View at Scopus
  12. H. Huynh, X. Yang, and M. Pollak, “Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells,” The Journal of Biological Chemistry, vol. 271, no. 2, pp. 1016–1021, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Rozen, J. Zhang, and M. Pollak, “Antiproliferative action of tumor necrosis factor-α on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation,” International Journal of Oncology, vol. 13, no. 4, pp. 865–869, 1998. View at Google Scholar · View at Scopus
  14. B. Liu, H.-Y. Lee, S. A. Weinzimer et al., “Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-α regulate transcriptional signaling and apoptosis,” The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33607–33613, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. L. J. Schedlich, M. K. O'Han, G. M. Leong, and R. C. Baxter, “Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 314, no. 1, pp. 83–88, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Ikezoe, S. Tanosaki, U. Krug et al., “Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells,” Blood, vol. 104, no. 1, pp. 237–242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Fanayan, S. M. Firth, A. J. Butt, and R. C. Baxter, “Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-β (TGF-β) and the type II TGF-β receptor,” The Journal of Biological Chemistry, vol. 275, no. 50, pp. 39146–39151, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Fanayan, S. M. Firth, and R. C. Baxter, “Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-β1 signaling,” The Journal of Biological Chemistry, vol. 277, no. 9, pp. 7255–7261, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. Butt, S. M. Firth, M. A. King, and R. C. Baxter, “Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells,” The Journal of Biological Chemistry, vol. 275, no. 50, pp. 39174–39181, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Takahashi, V. Papavero, J. Yuhas et al., “Altered expression of members of the IGF-axis in clear cell renal cell carcinoma,” International Journal of Oncology, vol. 26, no. 4, pp. 923–931, 2005. View at Google Scholar · View at Scopus
  21. A. Marimuthu, S. Chavan, G. Sathe et al., “Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome,” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1834, no. 11, pp. 2308–2316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Xue, C. J. Scarlett, C. J. Jackson, B. J. Allen, and R. C. Smith, “Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma,” Pancreas, vol. 36, no. 2, pp. 160–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Takaoka, H. Harada, C. D. Andl et al., “Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3,” Cancer Research, vol. 64, no. 21, pp. 7711–7723, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Xi, G. Nakajima, T. Hamil, O. Fodstad, A. Riker, and J. Ju, “Association of insulin-like growth factor binding protein-3 expression with melanoma progression,” Molecular Cancer Therapeutics, vol. 5, no. 12, pp. 3078–3084, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. D. E. Hansel, A. Rahman, M. House et al., “Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms,” Clinical Cancer Research, vol. 10, no. 18, pp. 6152–6158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. D. R. Clemmons, C. Camacho-Hubner, E. Coronado, and C. K. Osborne, “Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status,” Endocrinology, vol. 127, no. 6, pp. 2679–2686, 1990. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Figueroa, J. G. Jackson, W. L. McGuire, R. F. Krywicki, and D. Yee, “Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status,” Journal of Cellular Biochemistry, vol. 52, no. 2, pp. 196–205, 1993. View at Publisher · View at Google Scholar · View at Scopus
  28. Z.-M. Shao, M. S. Sheikh, J. V. Ordonez et al., “IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma,” Cancer Research, vol. 52, no. 18, pp. 5100–5103, 1992. View at Google Scholar · View at Scopus
  29. F. Pekonen, T. Nyman, V. Ilvesmaki, and S. Partanen, “Insulin-like growth factor binding proteins in human breast cancer tissue,” Cancer Research, vol. 52, no. 19, pp. 5204–5207, 1992. View at Google Scholar · View at Scopus
  30. J. L. Martin and R. C. Baxter, “Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/ mammalian target of rapamycin pathway,” Endocrinology, vol. 148, no. 5, pp. 2532–2541, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. L. Martin, H. C. De Silva, M. Z. Lin, C. D. Scott, and R. C. Baxter, “Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to egf receptor Blockade,” Molecular Cancer Therapeutics, vol. 13, no. 2, pp. 316–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. R. L. Rocha, S. G. Hilsenbeck, J. G. Jackson, A. V. Lee, J. A. Figueroa, and D. Yee, “Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features,” Journal of the National Cancer Institute, vol. 88, no. 9, pp. 601–606, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Yu, M. A. Levesque, M. J. Khosravi, A. Papanastasiou-Diamandi, G. M. Clark, and E. P. Diamandis, “Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer,” British Journal of Cancer, vol. 74, no. 8, pp. 1242–1247, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Yu, M. A. Levesque, M. J. Khosravi, A. Papanastasiou-Diamandi, G. M. Clark, and E. P. Diamandis, “Insulin-like growth factor-binding protein-3 and breast cancer survival,” International Journal of Cancer, vol. 79, no. 6, pp. 624–628, 1998. View at Google Scholar
  35. S. M. Sheen-Chen, H. Zhang, C. C. Huang, and R. P. Tang, “Insulin-like growth factor-binding protein-3 in breast cancer: analysis with tissue microarray,” Anticancer Research, vol. 29, no. 4, pp. 1131–1135, 2009. View at Google Scholar · View at Scopus
  36. S. M. Firth, S. Fanayan, D. Benn, and R. C. Baxter, “Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 325–329, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. A. J. Butt, J. L. Martin, K. A. Dickson, F. McDougall, S. M. Firth, and R. C. Baxter, “Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 4, pp. 1950–1956, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. S. M. de Mellow and R. C. Baxter, “Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts,” Biochemical and Biophysical Research Communications, vol. 156, no. 1, pp. 199–204, 1988. View at Publisher · View at Google Scholar · View at Scopus
  39. C. A. Conover, “Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism,” Endocrinology, vol. 130, no. 6, pp. 3191–3199, 1992. View at Publisher · View at Google Scholar · View at Scopus
  40. C. J. Grill and W. S. Cohick, “Insulin-like growth factor binding protein-3 mediates IGF-I action in a bovine mammary epithelial cell line independent of an IGF interaction,” Journal of Cellular Physiology, vol. 183, pp. 273–283, 2000. View at Publisher · View at Google Scholar
  41. C. McCaig, C. M. Perks, and J. M. P. Holly, “Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin,” Journal of Cell Science, vol. 115, no. 22, pp. 4293–4303, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Granata, L. Trovato, G. Garbarino et al., “Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways,” The FASEB Journal, vol. 18, no. 12, pp. 1456–1458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. J. L. Martin and R. C. Baxter, “Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells,” The Journal of Biological Chemistry, vol. 274, no. 23, pp. 16407–16411, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. C. A. Conover, “Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3,” Endocrinology, vol. 129, no. 6, pp. 3259–3268, 1991. View at Publisher · View at Google Scholar · View at Scopus
  45. J.-C. Chen, Z.-M. Shao, M. S. Sheikh et al., “Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line,” Journal of Cellular Physiology, vol. 158, no. 1, pp. 69–78, 1994. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Cohen, R. Rajah, J. Rosenbloom, and D. J. Herrick, “IGFBP-3 mediates TGF-β1-induced cell growth in human airway smooth muscle cells,” The American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 278, no. 3, pp. L545–L551, 2000. View at Google Scholar · View at Scopus
  47. J. L. Martin, S. M. Weenink, and R. C. Baxter, “Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases,” Journal of Biological Chemistry, vol. 278, no. 5, pp. 2969–2976, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Alshaker, L. Sauer, D. Monteil et al., “Therapeutic potential of targeting SK1 in human cancers,” Advances in Cancer Research, vol. 117, pp. 143–200, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. O. A. Sukocheva, L. Wang, N. Albanese, S. M. Pitson, M. A. Vadas, and P. Xia, “Sphingosine kinase transmits estrogen signaling in human breast cancer cells,” Molecular Endocrinology, vol. 17, no. 10, pp. 2002–2012, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. O. Sukocheva, C. Wadham, A. Holmes et al., “Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1,” The Journal of Cell Biology, vol. 173, no. 2, pp. 301–310, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. J. L. Martin, M. Z. Lin, E. M. McGowan, and R. C. Baxter, “Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity,” The Journal of Biological Chemistry, vol. 284, no. 38, pp. 25542–25552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Kobayashi, “Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance,” Breast Cancer, vol. 15, no. 2, pp. 153–158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. I. A. Mayer, V. G. Abramson, B. D. Lehmann, and J. A. Pietenpol, “New strategies for triple-negative breast cancer-deciphering the heterogeneity,” Clinical Cancer Research, vol. 20, no. 4, pp. 782–790, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Boyle, “Triple-negative breast cancer: epidemiological considerations and recommendations,” Annals of Oncology, vol. 23, no. 6, Article ID mds187, pp. vi7–vi12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. M. F. Press, R. S. Finn, D. Cameron et al., “HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer,” Clinical Cancer Research, vol. 14, no. 23, pp. 7861–7870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. R. S. Finn, M. F. Press, J. Dering et al., “Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer,” Journal of Clinical Oncology, vol. 27, no. 24, pp. 3908–3915, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. T.-C. Hsia, C.-Y. Tu, Y.-J. Chen et al., “Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells,” Molecular Pharmacology, vol. 83, no. 4, pp. 857–869, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. C. L. Griffiths and J. L. Olin, “Triple negative breast cancer: a brief review of its characteristics and treatment options,” Journal of Pharmacy Practice, vol. 25, no. 3, pp. 319–323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair, “Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues,” Molecular Interventions, vol. 7, no. 3, pp. 147–156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Gyorffy, A. Lanczky, A. C. Eklund et al., “An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients,” Breast Cancer Research and Treatment, vol. 123, no. 3, pp. 725–731, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. R. C. Baxter, “Insulin-like growth factor binding protein-3 (IGFBP-3): novel ligands mediate unexpected functions,” Journal of Cell Communication and Signaling, vol. 7, no. 3, pp. 179–189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Xia, J. R. Gamble, L. Wang et al., “An oncogenic role of sphingosine kinase,” Current Biology, vol. 10, no. 23, pp. 1527–1530, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Kohno, M. Momoi, M. L. Oo et al., “Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation,” Molecular and Cellular Biology, vol. 26, no. 19, pp. 7211–7223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Kawamori, T. Kaneshiro, M. Okumura et al., “Role for sphingosine kinase 1 in colon carcinogenesis,” The FASEB Journal, vol. 23, no. 2, pp. 405–414, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. L. A. Heffernan-Stroud, K. L. Helke, R. W. Jenkins, A.-M. de Costa, Y. A. Hannun, and L. M. Obeid, “Defining a role for sphingosine kinase 1 in p53-dependent tumors,” Oncogene, vol. 31, no. 9, pp. 1166–1175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. L. A. Heffernan-Stroud and L. M. Obeid, “Sphingosine kinase 1 in cancer,” Advances in Cancer Research, vol. 117, pp. 201–235, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. E. A. Bassett, W. Wang, F. Rastinejad, and W. S. El-Deiry, “Structural and functional basis for therapeutic modulation of p53 signaling,” Clinical Cancer Research, vol. 14, no. 20, pp. 6376–6386, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. L. Buckbinder, R. Talbott, S. Velasco-Miguel et al., “Induction of the growth inhibitor IGF-binding protein 3 by p53,” Nature, vol. 377, no. 6550, pp. 646–649, 1995. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Giuliano, M. Lauricella, E. Vassallo, M. Carabillò, R. Vento, and G. Tesoriere, “Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors,” Investigative Ophthalmology & Visual Science, vol. 39, no. 8, pp. 1300–1311, 1998. View at Google Scholar · View at Scopus
  70. C. A. Fowler, C. M. Perks, P. V. Newcomb, P. B. Savage, J. R. Farndon, and J. M. Holly, “Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells,” International Journal of Cancer, vol. 88, no. 3, pp. 448–453, 2000. View at Google Scholar
  71. R. Kawabata, S. Oie, M. Takahashi, H. Kanayama, T. Oka, and K. Itoh, “Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines,” International Journal of Oncology, vol. 38, no. 6, pp. 1489–1500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Nickerson, H. Huynh, and M. Pollak, “Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 237, pp. 690–693, 1997. View at Google Scholar
  73. Z. P. Gill, C. M. Perks, P. V. Newcomb, and J. M. P. Holly, “Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner,” The Journal of Biological Chemistry, vol. 272, no. 41, pp. 25602–25607, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. M. P. Achary, W. Jaggernauth, E. Gross, A. Alfieri, H. P. Klinger, and B. Vikram, “Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression,” Cytogenetics and Cell Genetics, vol. 91, no. 1–4, pp. 39–43, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Goto, M. Takano, M. Sakamoto et al., “Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers,” Oncology Reports, vol. 15, no. 5, pp. 1265–1271, 2006. View at Google Scholar · View at Scopus
  76. Y. Sun, S. Zheng, A. Torossian et al., “Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells,” International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 3, pp. e563–e572, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. I. I. de Caceres, M. Cortes-Sempere, C. Moratilla et al., “IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer,” Oncogene, vol. 29, no. 11, pp. 1681–1690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. S. B. Vestey, C. M. Perks, C. Sen, C. J. Calder, J. M. P. Holly, and Z. E. Winters, “Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome,” Breast Cancer Research, vol. 7, no. 1, pp. R119–R129, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Skog, Q. He, R. Khoshnoud, T. Fornander, and L.-E. Rutqvist, “Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line,” Tumor Biology, vol. 25, no. 1-2, pp. 41–47, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Z. Lin, K. A. Marzec, J. L. Martin, and R. C. Baxter, “The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents,” Oncogene, vol. 33, no. 1, pp. 85–96, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. S. P. Jackson and J. Bartek, “The DNA-damage response in human biology and disease,” Nature, vol. 461, no. 7267, pp. 1071–1078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. I. Brandsma and D. C. Gent, “Pathway choice in DNA double strand break repair: observations of a balancing act,” Genome Integrity, vol. 3, article 9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. D. J. Chen and C. S. Nirodi, “The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage,” Clinical Cancer Research, vol. 13, no. 22, pp. 6555–6560, 2007. View at Publisher · View at Google Scholar · View at Scopus